Lv5
1035 积分 2021-01-25 加入
PDA/ANSI Standard 07-2026: Analytical Procedure Transfer, Comparability, and the Use of Platform Analytical Procedures for Biologics
3天前
求助中
《基因治疗药品范围和归类技术指导原则（2026年版）》解读与展望
3天前
已完结
《细胞治疗药品范围和归类技术指导原则（2026年版）》解读与展望
8天前
已完结
《基因治疗药品范围和归类技术指导原则（2026年版）》解读与展望
8天前
已完结
EuLV™ Stable Cell Line Platform: Overcoming CAR-T Therapy Manufacturing Bottlenecks to Enable Scalable and Cost-Effective Lentiviral Vectors Production
9天前
已完结
EuLV™ Stable Cell Line Platform: Overcoming CAR-T Therapy Manufacturing Bottlenecks to Enable Scalable and Cost-Effective Lentiviral Vectors Production
17天前
已完结
Mitigation of pre-existing immunogenicity in ADA method development
23天前
已完结
Early pre-existing anti-drug antibody screening in biotherapeutic development: a cross-company perspective
23天前
已完结
Lentiviral In Vivo CD19 CAR T-Cell Therapy in Neurologic Autoimmune Disorders
25天前
已完结
Lentiviral In Vivo CD19 CAR T-Cell Therapy in Neurologic Autoimmune Disorders
25天前
已完结
皖公网安备34019202002308
